Abstracts Archive - Page 2157 of 2425 - ACR Meeting Abstracts

Abstract Number: 1408 • 2013 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated With a Reduced Long Term Risk Of Rheumatoid Arthritis In Men
Carl Turesson¹, Ulf Bergström², Mitra Pikwer², Jan-Åke Nilsson² and Lennart Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: There are diverging results on the relation between body mass index (BMI) and risk of rheumatoid arthritis (RA). From a previous nested case-control study,…
Abstract Number: 1409 • 2013 ACR/ARHP Annual Meeting
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Edward C. Keystone¹, Ferdinand C. Breedveld², Désiréé van der Heijde², Robert Landewe³, Stefan Florentinus⁴, Udayasankar Arulmani⁵, Shufang Liu⁵, Hartmut Kupper⁶ and Arthur Kavanaugh⁷, ¹University of Toronto, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Medical Center, Amsterdam, Netherlands, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷University of California San Diego, San Diego, CA
Background/Purpose: The PREMIER trial demonstrated the superiority of initial adalimumab (ADA)+MTX vs the individual monotherapies in MTX-naïve patients (pts) with early, aggressive rheumatoid arthritis (RA).…
Abstract Number: 1410 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Improves Left Ventricular Mass and Cardiac Output in Patients With Rheumatoid Arthritis. A Cohort Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Toshikatsu Kanazawa², Hiroshi Komori³, Hiroyuki Ohta⁴, Kuniki Amano⁵ and Noriko Kuwaba⁶, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology, hiroshima clinic, hiroshima, Japan, ³internal medicine, hiroshima clinic, hiroshima, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Rheumatology, Sky Clinic, Hiroshima, Japan, ⁶Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Rheumatologists need to develop primary prevention strategies for cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients. We reported tocilizumab (TCZ) improved arterial stiffness as…
Abstract Number: 1411 • 2013 ACR/ARHP Annual Meeting
The Peroxisome Proliferator Activated Receptor-gamma pioglitazone Decreases Cardiovascular Risk and Disease Activity In Patients With Rheumatoid arthritis
Wendy Marder¹, Shokoufeh Khalatbari², James D. Myles³, Rita Hench⁴, Susan Lustig⁴, Srilakshmi Yalavarthi⁵, Aishwarya Parameswaran⁴, Robert Brook² and Mariana J. Kaplan⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Medicine, University of Michigan at Ann Arbor, Ann Arbor, MI, ³Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan Rheumatology, Ann Arbor, MI, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease (CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote…
Abstract Number: 1412 • 2013 ACR/ARHP Annual Meeting
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Eva Dokoupilova¹, Slawomir Jeka², Jiri Vencovsky³, Janusz Badurski⁴, Klaas Prins⁵, Vibeke Strand⁶, Edward C. Keystone⁷, Ronald F van Vollenhoven⁸, Jurgen Wollenhaupt⁹, Andrea Wartenberg-Demand¹⁰, Gabriele Niemann¹⁰, Ahmed Abufarag¹⁰, Silke Aigner¹⁰, Sibylle Kaiser¹⁰, Faiza Rharbaoui¹⁰, Niklas Czeloth¹¹, Ralf Wolter¹⁰, Benjamin Dälken¹⁰ and Thorsten Holzkämper¹⁰, ¹Medical Plus s.r.o, Uherske Hradiste, Czech Republic, ²Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁵qPharmetra, Nijmegen, Netherlands, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁰Biotest AG, Dreieich, Germany, ¹¹Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…
Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Edward Keystone¹, Robert Landewé², Ronald van Vollenhoven³, Bernard Combe⁴, Vibeke Strand⁵, Philip J. Mease⁶, Laura Shaughnessy⁷, Brenda VanLunen⁷ and Désirée van der Heijde⁸, ¹University of Toronto, Toronto, ON, Canada, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Montpellier University Hospital, Montpellier, France, ⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁷UCB Pharma, Raleigh, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Edward Keystone¹, Mark C. Genovese², Stephen Hall³, Pedro Miranda⁴, Sang-Cheol Bae⁵, Chenglong Han⁶, Timothy A. Gathany⁶, Yiying Zhou⁷, Stephen Xu⁸ and Elizabeth C. Hsia⁸, ¹University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Stanford University, Palo Alto, CA, ³Cabrini Medical Centre, Melbourne, Australia, ⁴Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Janssen Global Services, LLC., Malvern, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…
Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Takao Koike¹, Masayoshi Harigai², Naoki Ishiguro³, Shigeko Inokuma⁴, Junnosuke Ryu⁵, Syuji Takei⁶, Tsutomu Takeuchi⁷, Y. Tanaka⁸, Masahiko Watanabe⁹ and Hisashi Yamanaka¹⁰, ¹Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Department of Allergy and Rheumatology diseases, Japanese Red Cross Medical Center, Tokyo, Japan, ⁵Nihon University School of Medicine, Tokyo, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Bristol-Myers K.K, Tokyo, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…
Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Zhanguo Li¹, Fengchun Zhang², Jonathan Kay³, Kaiyin Fei⁴, Chenglong Han⁵, Yanli Zhuang⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…
Abstract Number: 1390 • 2013 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections
Stanley J. Naides, Olga S Zhukov, Rania W Abolhosn and Joanna M Popov, Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Background/Purpose: The 14-3-3 proteins are ubiquitously-expressed intracellular chaperonins. Expression of the η (eta) isoform is restricted to synovial and CNS tissues. Extracellular 14-3-3η induces proinflammatory…
Abstract Number: 1377 • 2013 ACR/ARHP Annual Meeting
Decoy Receptor 3 Regulates the Expression of Tryptophan Hydroxylase TPH1 in Rheumatoid Synovial Fibroblasts
Toshihisa Maeda¹, Yasushi Miura², Koji Fukuda³, Shinya Hayashi⁴ and Masahiro Kurosaka¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan, ³Dept. of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Tryptophan hydroxylase (TPH) which catalyzes the hydroxylation of L-tryptophan is the rate-limiting enzyme involved in the synthesis of serotonin. TPH has two isoforms; TPH1…
Abstract Number: 1378 • 2013 ACR/ARHP Annual Meeting
Associations Of Periodontitis (PD) With Established Seropositive Rheumatoid Arthritis are Independent of Smoking and Other Risk Factors
Ted R. Mikuls¹, Jeffrey Payne², Fang Yu³, Geoffrey M. Thiele⁴, Richard J. Reynolds⁵, Grant W. Cannon⁶, Jeffrey Markt⁷, David McGowan⁸, Gail S. Kerr⁹, Robert Redman¹⁰, Andreas M. Reimold¹¹, Garth Griffiths¹², Mark Beatty², Shawneen Gonzalez², Debra Bergman¹³, Bartlett C. Hamilton III¹⁴, Alan R. Erickson¹ and James R. O'Dell¹⁵, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Otol-Head and Neck Surgery, University of Nebraska Medical Center, Omaha, NE, ⁸Dentistry, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹⁰Dentistry, Washington DC VA, Georgetown and Howard University, Washington, DC, ¹¹Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹²Dentistry, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹⁴University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ¹⁵Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) has been proposed as a risk factor in RA. Reports have suggested that this association may be due to confounding from smoking…
Abstract Number: 1379 • 2013 ACR/ARHP Annual Meeting
Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
Toshihiro Tono¹, Yoshiyuki Arinuma², Tatsuo Nagai³, Sumiaki Tanaka² and Shunsei Hirohata², ¹Int Med/Rheumatol & Infec Dis, Kitasato University school of medicine, sagamihara, Japan, ²Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ³Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Biological agents inhibiting proinflammatory cytokines, especially IL-6 and TNFa, have brought a great impact in the treatment of rheumatoid arthritis (RA). In addition, CTLA4-Ig…
Abstract Number: 1380 • 2013 ACR/ARHP Annual Meeting
Histone Modifications In The Interluekin-6 Gene Promoter Region Of Rheumatoid Arthritis Synovial Fibroblasts
Takuma Tsuzuki Wada^1,2, Yasuto Araki^1,2, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Kojiro Sato¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: , Rheumatoid arthritis (RA) is a disease of unknown origin, which develops continuous inflammation and progressive joint destruction resulting from an autoimmune response mainly…
Abstract Number: 1381 • 2013 ACR/ARHP Annual Meeting
The ZC3HC1 rs11556924 Polymorphism Is Associated With Increased Carotid Intima-Media Thickness In Patients With Rheumatoid Arthritis
Raquel lopez Mejias¹, Fernanda Genre², Mercedes García-Bermúdez³, Alfonso Corrales⁴, Carlos González-Juanatey⁵, J. Llorca⁶, Encarnación Amigo⁷, Jose A. Miranda-Filloy⁸, Javier Rueda-Gotor¹, Ricardo Blanco¹, Santos Castañeda⁹, Javier Martin¹⁰ and Miguel A. Gonzalez-Gay¹¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain., Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁵Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ⁶Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁷Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁸Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ¹⁰Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, ¹¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a complex polygenic disease associated with chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. A recent meta-analysis has described…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].